Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Washington for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Washington only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Washington (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Kenneth Bergman (NPI 1669443032)

Field	Value
Entity Type	Individual
Organization	Kenneth Bergman
Address	11511 Canterwood Blvd Nw
City	Gig Harbor
State	WA
ZIP	98332
Taxonomy	Radiation Oncology Physician
NPI Enumerated	February 1, 2006

Payer Source	Total Paid
Medicare	$2.2M
Medicaid	$0

Key Findings

This provider’s Medicare activity is the primary commercial footprint: total Medicare revenue on file is $2.2M and there is no Medicaid billing on file, making the practice effectively single‑payer (Medicare) in the available data. Analysts should treat Medicaid exposure as nonexistent for comparative contracting or utilization risk analyses.

Revenue is highly concentrated in a small set of radiology/radiopharmaceutical services: A9607 alone accounts for $1.3M (60.3% of the provider’s Medicare revenue) and the precomputed top‑3 codes together account for 78.0% of Medicare revenue. That concentration indicates a heavy dependence on a few high‑value items rather than a broad, diversified Medicare billing base.

The code mix points to a radiation oncology practice built around radioligand therapy and in‑house advanced imaging: dominant A9607 (Lutetium lu 177 vipivotide tetraxetan) is accompanied by high‑revenue PET/CT imaging codes such as 78815 and multiple radiopharmaceutical diagnostics (A9595, A9596, A9552). This combination suggests the provider delivers both diagnostic PET services and therapeutic radiopharmaceuticals as core service lines rather than only external beam therapy.

Competitive standing varies by service line. For A9607 the provider ranks #24 of 44 nationally (47th percentile; typical, unremarkable volume for this code), indicating a modest, non‑dominant national position in lutetium therapy; by contrast 78815 ranks #1314 of 6566 (80th percentile; typical, unremarkable volume for this code), showing relatively stronger PET/CT imaging activity versus national peers. G6015 (IMRT delivery) sits at #549 of 1429 (62th percentile; typical, unremarkable volume for this code), consistent with a routine but not leading profile in advanced delivery technologies.

There are clear statistical nuances within the radiopharmaceutical mix: A9596 (Gallium ga-68 gozetotide) appears at low national volume with a ranking of #161 of 168 (4th percentile; typical, unremarkable volume for this code), while A9595 and A9552 show more mid‑range positioning (A9595 at #314 of 528, 40th percentile; A9552 at #456 of 2411, 81th percentile; all labeled typical, unremarkable volume for these codes). This suggests selective adoption of specific PET tracers rather than uniform use across all radiopharmaceutical diagnostic agents.

Operationally, dependence on a single high‑cost therapeutic code (A9607 at $1.3M) implies that reimbursement changes, supply constraints, or coverage policy shifts for that agent would disproportionately affect the provider’s Medicare revenue. Risk assessment and contract negotiations should prioritize monitoring of radiopharmaceutical reimbursement and access.

The provider has an established NPI tenure (enumerated 2006-02-01, ~20 years ago), indicating a long‑standing practice presence that may have supported adoption of advanced imaging and radioligand therapy over time. Tenure combined with the concentrated revenue profile is consistent with a mature specialist practice focused on a narrow set of high‑value oncology procedures.

Claims for planning and delivery (examples include 77301, 77373, 77427, 77280 and 77290) alongside the high‑revenue diagnostic and therapeutic codes indicate an integrated radiation oncology workflow from simulation and treatment planning through delivery and radiopharmaceutical therapy. For payers analyzing network value or continuity of care, this mix signals capacity to provide end‑to‑end cancer imaging and treatment services rather than only discrete referrals for external components of care.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

29 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
A9607	Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie	7,000	$190	$1.3M
G6015	Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session	720	$290	$211.3K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	160	$1,170	$184.3K
A9595	Piflufolastat f-18, diagnostic, 1 millicurie	180	$470	$83.7K
77014	N/A	820	$100	$80.1K
A9596	Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie	60	$840	$47K
77301	Intensity modulated radiotherapy (IMRT) uses advanced computer technology to deliver very precise radiation beams that target and destroy the cancerous cells while avoiding the surrounding healthy…	30	$1,490	$46.1K
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	150	$280	$40.4K
78816	The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The…	30	$1,140	$34.1K
77373	This code represents the technical component of a procedure in which the provider performs stereotactic body radiation therapy. The therapy uses a three–dimensional coordinate system to locate small…	40	$820	$30.3K

Showing 1–10 of 29

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 29 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Washington Distribution

Kenneth Bergman — 0 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Washington

Full comparison — all codes billed, vs. state median

29 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
A9607	2	10	7,000	$190	$1.7M
G6015	15	30	650	$290	$204.1K
A9596	9	10	180	$830	$183K
A9595	10	10	200	$480	$150.1K
78815	23	110	50	$430	$50.3K
77373	14	20	40	$810	$40.3K
77014	28	120	450	$60	$32.7K
77301	49	90	30	$770	$28.5K
77427	43	110	150	$150	$26.5K
A9552	8	40	50	$280	$23.8K

Showing 1–10 of 29

Related Providers

Other providers that share a Tax Identification Number (TIN) with Kenneth Bergman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Kevin Sanders	WA	Radiation Oncology Physician	$4.5M	$0
Wendy Gao	WA	Radiation Oncology Physician	$772.5K	$0
Peninsula Rad Onc Ctr LLC	WA	Radiology Clinic/Center	$730.9K	$0
Nathan Bittner	WA	Radiation Oncology Physician	$568.9K	$0
Ann Pittier	WA	Radiation Oncology Physician	$549.6K	$0
Herbert Wang	WA	Radiation Oncology Physician	$514.5K	$0
Brent Tinnel	WA	Radiation Oncology Physician	$215.6K	$0
Dean Mastras	WA	Radiation Oncology Physician	$161.7K	$0

Nearby Providers

Other providers in the same ZIP code as Kenneth Bergman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Franciscan Health System	WA	General Acute Care Hospital	$0	$14.3M
Pierce County Fire District 5	WA	Land Ambulance	$642.3K	$7.6M
Harbor Plastic Surgery Center PLLC	WA	Ambulatory Surgical Clinic/Center	$612.4K	$0
Justin Piasecki	WA	MOHS-Micrographic Surgery Physician	$545.6K	$0
Raed Fahmy	WA	Cardiovascular Disease Physician	$178.4K	$0
Francisco Victor Beltran	WA	Internal Medicine Physician	$160.7K	$0
Lance Bear	WA	Orthopaedic Surgery Physician	$101K	$0
Arpun Bajwa	WA	Orthopaedic Surgery Physician	$85.3K	$0
Christopher Tepera	WA	Urology Physician	$75.6K	$0
Matthew Webber	WA	Gerontology Nurse Practitioner	$72.6K	$0

Kenneth Bergman — Billing Profile & Reimbursement Data

Sign up for Kenneth Bergman — Billing Profile & Reimbursement Data policy alerts

Kenneth Bergman — Billing Profile & Reimbursement Data

Sign up for Kenneth Bergman — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References